KDNY vs. AMLX, XNCR, VRNA, IRWD, RCKT, FGEN, ZNTL, SLRN, GERN, and DICE
Should you be buying Chinook Therapeutics stock or one of its competitors? The main competitors of Chinook Therapeutics include Amylyx Pharmaceuticals (AMLX), Xencor (XNCR), Verona Pharma (VRNA), Ironwood Pharmaceuticals (IRWD), Rocket Pharmaceuticals (RCKT), FibroGen (FGEN), Zentalis Pharmaceuticals (ZNTL), Acelyrin (SLRN), Geron (GERN), and DICE Therapeutics (DICE). These companies are all part of the "pharmaceutical preparations" industry.
Chinook Therapeutics vs.
Chinook Therapeutics (NASDAQ:KDNY) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
Chinook Therapeutics received 11 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Amylyx Pharmaceuticals an outperform vote while only 60.47% of users gave Chinook Therapeutics an outperform vote.
Chinook Therapeutics has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500.
Amylyx Pharmaceuticals has a net margin of 0.00% compared to Chinook Therapeutics' net margin of -4,114.05%. Chinook Therapeutics' return on equity of -47.13% beat Amylyx Pharmaceuticals' return on equity.
Chinook Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks.
Chinook Therapeutics currently has a consensus price target of $35.83, suggesting a potential upside of 52.29%. Amylyx Pharmaceuticals has a consensus price target of $50.17, suggesting a potential upside of 93.17%. Given Amylyx Pharmaceuticals' higher possible upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Chinook Therapeutics.
93.9% of Chinook Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Amylyx Pharmaceuticals shares are owned by institutional investors. 16.8% of Chinook Therapeutics shares are owned by company insiders. Comparatively, 12.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Amylyx Pharmaceuticals had 8 more articles in the media than Chinook Therapeutics. MarketBeat recorded 11 mentions for Amylyx Pharmaceuticals and 3 mentions for Chinook Therapeutics. Chinook Therapeutics' average media sentiment score of 0.55 beat Amylyx Pharmaceuticals' score of 0.40 indicating that Chinook Therapeutics is being referred to more favorably in the media.
Summary
Chinook Therapeutics beats Amylyx Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KDNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chinook Therapeutics Competitors List
Related Companies and Tools
